The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health seeks to partner with one or more biomedical companies in developing protein nanoparticles for the display of viral epitopes for vaccine use.
The Cooperative Research and Development Agreement (CRADA) would require the following capabilities:
- Produce scaled- up purified recombinant protein nanoparticles
- Measure antibody levels/titers elicited by nanoparticles
- Measure neutralization capacity of antibodies to a panel of influenza viruses
- Produce hydridomas or cDNA clones of neutralizing antibody genes elicited by nanoparticles
- Produce quantities of antibodies sufficient for challenge and protection studies in animal models
CRADA partners will be expected to carry out additional immunogenicity studies in small animal mouse models with NIAID’s protein nanoparticles and if the data are promising, clinical studies may be discussed. It is especially desired that a prospective CRADA partner has expertise in performing and analyzing vaccination of animals with influenza immunogens/viruses and has the ability to perform challenge and protection studies in animals with a candidate influenza vaccine to expand on the initial studies performed by NIAID.
Additional details are available via FedBizOpps Solicitation Number: NIAID-TTIPO-2016-032.
